Dong-A ST
Biosimilar developer, South Korea. 1 development product across 1 molecule: ustekinumab.
First approval in the Atlas: Oct 2024, Imuldosa, ustekinumab (FDA)
FDAproducts approved1
EMAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered1
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Ustekinumab | Imuldosa DMB-3115 | Oct 2024 | Dec 2024 | · | · | · | May 2025 |
Month shown is the first approval or registration of that product in that market.
Chronology
- FDAOct 2024Imuldosa, ustekinumab
- EMADec 2024Imuldosa, ustekinumab
- EDEMay 2025Imuldosa, ustekinumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.